AnPac Bio Announces Positive Results from a Multi-Year Lung Cancer Prognosis and Recurrence Clinical Study

SAN JOSE, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, announced today positive results from a successfully completed a multi-year lung cancer prognosis and recurrence study in collaboration with a major hospital in China. The clinical study began in 2014, with the enrollment and completed all follow-up and testing in 2020. Approximately 1,000 confirmed lung cancer patients were tested in the clinical study using AnPac Bio’s cancer differentiation analysis (CDA) technology for prognosis and recurrence utility evaluations throughout initial diagnosis, surgery, chemotherapy and other treatments, and remission (for recurrence monitoring).

Initial results from the study indicate that CDA technology could act as a viable tool for measuring and evaluating (1) lung cancer treatment and efficacy and (2) recurrence following remission. Furthermore, AnPac Bio believes that compared with many competing methods, CDA technology, which is based on bio-physical signals in the blood, is more cost effective. A summary of the results from this multi-year clinical study are as follows:

• CDA value is a good indicator of a patient’s response to treatment. CDA values are statistically different between complete response (CR) patient group and stable disease (SD) patient group, and between CR patient group and progressive disease (PR) patient group, indicating that CDA could be used for cancer prognosis.
• Patient groups with higher CDA values (higher cancer risk or progression) have statistically lower five-year survival probability than patient groups with lower CDA values (lower cancer risk or progression) which shows that CDA values could be a good indicator predicting the outcome of a treatment (survival probability).
• In a number of cases, CDA values increased ahead of the onset of the cancer’s recurrence, indicating that CDA technology could potentially be used as a recurrence monitor.

Dr. Chris Yu, AnPac Bio’s Chairman and CEO commented: "We are very pleased with the positive results from this multi-year, major clinical study. The results show that CDA is not only suited for cancer screening and cancer prevention purposes, but can also be a viable tool for cancer prognosis and recurrence monitoring. Additional clinical studies will be carried out to provide further validation for these encouraging results.”